For cardiogenic shock and few clinical trials have been ... But the 2024 DanGer Shock trial showed that a microaxial flow pump (Impella CP) significantly improved survival compared with standard ...

"The DanGer Shock RCT results provide the highest level of scientific evidence demonstrating that Impella CP increases survival in patients with cardiogenic shock secondary to STEMI, which led the ...

Despite advances in the treatment of myocardial infarction (MI), the incidence of cardiogenic shock has remained at 7% to 10% during the last 25 years. Hospital mortality was about 90% in the ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Patients with severe heart failure or cardiogenic shock often require assistance from MCS devices such as venoarterial ...

Compared with standard medical care, early use of a temporary intra-aortic balloon pump (IABP) to support heart function in patients who were critically ill with cardiogenic shock caused by heart ...

Get Instant Summarized Text (Gist) Early use of an intra-aortic balloon pump (IABP) in patients with cardiogenic shock due to heart failure did not improve 60-day survival or facilitate transition ...

Intra-aortic balloon pump did not outperform standard therapy in cardiogenic shock, with similar survival rates and adverse events. Tirzepatide reduced cardiovascular events and improved symptoms ...

A risk-standardized model that includes patient factors, such as age and cardiogenic shock, can predict in-hospital mortality in patients with AMI. A new risk-standardized model can predict in ...